Navigation Links
Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research
Date:5/12/2008

New York, N.Y. May 13, 2008 Johnson & Johnson today announced that Professor Marc Feldmann, FMedSci, FAA, FRS and Emeritus Professor Sir Ravinder N. Maini, FRCP, FMedSci, FRS of the Kennedy Institute of Rheumatology, Imperial College London have been named the recipients of the 2008 Dr. Paul Janssen Award for Biomedical Research by an independent selection committee of world-renowned scientists.

The award salutes the most passionate and creative scientists in basic or clinical research, whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. Feldmann and Maini were selected for their role in the discovery of tumor necrosis factor-alpha, or TNF-alpha, as an effective therapeutic target for rheumatoid arthritis and other chronic inflammatory conditions afflicting millions worldwide. The award, which includes a $100,000 prize, will be presented to the winners at events in New York and Beerse, Belgium in September.

According to Solomon Snyder, Ph.D., Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine and Chairman, Janssen Award Selection Committee, The work of Feldmann and Maini exemplifies the bench-to-bedside approach that Paul Janssens contributions epitomized. It is extremely rare for researchers to identify a molecular messenger in test tube studies, demonstrate its physiologic relevance in animals and themselves carry these efforts forward to a successful clinical demonstration. Feldmann and Maini did all of this, leading to therapeutic agents of inestimable, lifesaving importance.

Established by Johnson & Johnson, the Dr. Paul Janssen Award for Biomedical Research honors the founder of Janssen Pharmaceutica. Known to his colleagues as Dr. Paul, Janssen was one of the 20th century's most gifted and passionate researchers, a physician-scientist who helped save millions of lives through his contribution to the discove
'/>"/>

Contact: Emily Zanovich
ezanovich@pnlifesciences.com
212-601-8278
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
2. General Atlantic and Hellman & Friedman Purchase HLTH Corporations Remaining Interest in Emdeon
3. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
4. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Micrus Endovascular Corporation
5. Law Offices of Howard G. Smith Announces 14 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Care Investment Trust Inc.
6. Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
7. MES Solutions Awarded VA Contract to Administer C&P Exams for Veterans
8. Two Michigan Asthma Management Programs Win EPA National Award
9. Keck Futures Initiative awards $1M for 15 research projects
10. Brainfood Awarded $25,000 Grant from General Mills Foundation through DC Mayor Fentys New Health Communities Program
11. Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...nversations with alleged lesbian pal deejay Samant... Girls' star kept in touch with her friends and re... magazine the access to the starlet's passionate c...n. In the conversations that appear under the tit...
...otect against the clustering of abnormal body chem... study in the Journal of Epidemiology and Communit...eased risk of diabetes, coronary artery disease, a...based on a representative sample of 2375 men aged ...
... Physicians (UK), the state of emergency services... audit entitled Myocardial Infarction National Aud...all in the percentage of people killed by heart at...wn 12.4 percent from last years figures, meaning 1...
...tion programs in low and middle-income countries, ...am unit costs to reduce . A UCSF-led team of rese... Other low and middle-income countries like Uganda... Russia were also assessed. "With the recent rep...
Other Medicine News:Health News:Survey Shows Emergency Services Of British Hospitals Doing A Good Job 2
(Date:8/14/2008)...Newswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: ...mmitted to,discovering, developing and commerciali...ed unaudited financial results for the third fisca... a net loss attributable to,common stockholders of...he,quarter ended June 30, 2008, as compared to a n...
(Date:8/14/2008)...14 /- The Clinical Trials,Bootcamp an...hysicians,clinical coordinators, clinical researc...It will be held in Boca Raton at the Boca Resort f...inical coordinators, monitors and,other industry p...orporate,clinical trials into a practice, as well ...
(Date:8/14/2008)...begin in late 2008 or in early 2009 -, SAN CARLOS..., Inc.,(Nasdaq: NUVO ) today announced positive r... NU172, demonstrating that the direct thrombin,inh...tion with a rapid,return toward baseline after the... "NU172 has the potential to address many of the l...
(Date:8/13/2008)...-FirstCall/ -- As biotechnology,pharmaceutical an...cal,trials beyond their own borders to other parts...uth America, complicated regulatory environments,c...rding to an analysis by,Aon Corporation (NYSE: AO...those companies a visual representation of the com...
Breaking Medicine Technology:Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 1Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 2Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 3Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 4Dead clams tell many tales 1007 1Dead clams tell many tales 1007 2Dead clams tell many tales 1007 3Dead clams tell many tales 1007 4Tiny radioactive spheres effectively treat cancer that has spread to the liver 4844 1Tiny radioactive spheres effectively treat cancer that has spread to the liver 4844 2New treatment option studied for bladder cancer 4839 1New treatment option studied for bladder cancer 4839 2New treatment option studied for bladder cancer 4839 3
...curs at the 55th Annual,Clinical Meeting of the Am... COLLEGEVILLE, Pa., May 09, 2007 /PRNewswire-First...h , presented results from the,first Phase 3 studi... treatment of moderate-to-severe vasomotor symptom...enopause. These studies showed,that women who took...
...- Results of a Phase 2a,clinical trial evaluating ...eat hospital acquired gram-negative bacterial,pneu...ociety (ATS),International Conference, May 18 - 23...S. Niederman, MD, Chairman, Department of, ...or of, Medicine; Vice Chairman, Departme...
Other Medicine Technology:Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: